Dulaglutide trial completed in adults with obesity without diabetes

A Phase 3 trial comparing weekly dulaglutide with semaglutide and tirzepatide in adults with obesity without diabetes was recorded as completed on 13 April 2026. The study enrolled 150 participants and planned to assess changes in weight, BMI, lipid profile and liver function over six months; the supplied record contains no outcome measurements.

Background

The study evaluated dulaglutide, listed alongside semaglutide and tirzepatide, in adults with obesity who did not have diabetes. The registry lists non-diabetic obesity and obesity as the conditions under study. The supplied information does not describe the drugs’ mechanisms, prior approvals for this population, or the prevalence of the condition, so it does not support broader claims about their use or effects.

Trial design

This completed Phase 3 randomized controlled trial, identified as NCT07834398, enrolled 150 participants. Its summary describes adults with a BMI greater than 30 who were assigned to three groups receiving dulaglutide, semaglutide or tirzepatide. Participants were to be followed for six months. Planned assessments included changes in weight, BMI, lipid profile and liver function. The registry data supplied here do not list a primary-outcome entry or provide details on allocation, treatment doses or statistical methods.

What this means

Completion marks the end of the study, but the information provided does not report whether dulaglutide improved any measured outcome or how it compared with semaglutide or tirzepatide. No numerical results, statistical analyses or adverse-event summary were supplied. Clinicians and researchers therefore cannot use this record alone to judge comparative efficacy or safety in adults with obesity without diabetes. The trial’s planned measures indicate what it set out to assess, not what it found.

Source

Source: ClinicalTrials.gov, study registry record for “Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes,” with the trial recorded as completed on 13 April 2026. Available at clinicaltrials.gov/study/NCT07834398.